Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 ...

Experts agree that combination approaches, which may or may not include chemotherapy, will drive improved patient outcomes in ...

BrYet US, Inc. (“BrYet”) — a biotechnology innovator focused on developing curative therapies for advanced cancers — ...

ALX Oncology (NASDAQ:ALXO) outlined progress across its two core programs—CD47 blocker evorpacept and EGFR-targeted ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') announced that the latest long-term survival analysis data from the China ...

Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains ...

New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026IM-1021 Phase 1 ongoing with initial data expected in 2026Three IND submissions for solid ...

Molecularly targeted therapies are increasingly relevant in clinical oncology, as they enable the selective modulation of specific biologic targets—such as enzymes or receptors—by inhibiting or ...

Telix reported FY2025 revenue of $804M, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622M. Read why TLX stock is a Buy.

Conference Call Begins at 4:30 p.m. Eastern Time TodayEMERYVILLE, Calif.--(BUSINESS WIRE)--$OABI #OABI--OmniAb, Inc. (NASDAQ: ...